Cipher Pharmaceuticals (TSE:CPH) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cipher Pharmaceuticals announced that their partner, Moberg Pharma, reported disappointing results from a Phase 3 study of MOB-015, a nail fungus treatment, which did not meet its primary endpoint. Despite this setback, Cipher remains focused on its recent acquisition of the Natroba business and sees significant growth potential in the U.S. and international markets.
For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue